Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCA | P17252 | 1/20 | 0.59 |
| ▸ | MMP12 | P39900 | 1/20 | 0.59 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.43 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.39 |
| ▸ | CCKBR | P32239 | 4/20 | 0.37 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.35 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.35 |
| ▸ | PRKAB1 | Q9Y478 | 1/20 | 0.35 |
| ▸ | KMO | O15229 | 1/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3571241 | 0.96 | PRKCA (0.59) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL12427909 | 0.95 | PRKCA (0.58) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL12427728 | 0.95 | PRKCA (0.58) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL12428102 | 0.92 | PRKCA (0.59) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL12427928 | 0.92 | PRKCA (0.59) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL12427843 | 0.92 | PRKCA (0.53) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL12427884 | 0.92 | PRKCA (0.53) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL803976 | 0.91 | PRKCA (0.52) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL12427797 | 0.91 | PRKCA (0.51) | PRKCAMMP12NR1I2SCN9ACCKBR | |
| SCHEMBL4200779 | 0.91 | PRKCA (0.49) | PRKCAMMP12NR1I2SCN9ACYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | JAPAN TOBACCO INC. (JP) | 2012-03-22 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-7977331-B1 | Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor | JAPAN TOBACCO INC. (JP) | 2011-07-12 | — | — | US | disclosed |
| US-20090149526-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2009-06-11 | — | — | US | disclosed |
| EP-1926733-A2 | TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | Istituto di Ricerche di Biologia Molecolare P. Angeletti (IT) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007029029-A2 | TETRACYCLIC INDOLE DERIVATIVES AS ANTIVIRAL AGENTS | ISTITUTO DI RICERCHE DI BIOLOGIA MOLECOLARE P. ANGELETTI SPA (IT) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149526-A1 | Tetracyclic Indole Derivatives as Antiviral Agents | IDO1, ZC3HAV1, ZC3HAV1L | PRKCA 4063/4885MMP12 3442/4885NR1I2 142/4885 |
| US-20120070409-A1 | TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR | POLI, TERT, ZC3HAV1 | PRKCA 2404/4885MMP12 1013/4885NR1I2 1189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.